Axogen, Inc.
Close on Oct 19, 2026
- Market cap
- $1.88B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 28, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 29, 2026 | Before market open | $69.70M | $-0.03 | $0.12 |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 28, 2026 | Before market open | $61.50M | $-0.38 | $0.07 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 24, 2026 | Before market open | $59.90M | $-0.28 | $0.07 |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 29, 2025 | Before market open | $60.10M | $0.01 | $0.12 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | $56.70M | $0.01 | $0.12 |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | $48.60M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 25, 2025 | Before market open | $49.40M | $0.01 | $0.07 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | $48.60M | $-0.04 | $0.07 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 5, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Jul 29, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| gross margin | full-year | 73% | Lowered |
| revenue | full-year | $279.00M | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Axogen filed with the SEC
Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
Regulation FD disclosure · EX-99.1 to Form 8-K
Making Nerve Repair an Expected Standard of Care Company Overview September 2026
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K/A
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Making Nerve Repair an Expected Standard of Care Company Overview September 2026 CONFIDENTIAL
Material agreement · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Axogen Announces Pricing of $208.7 Million
Material agreement · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Axogen, Inc. Reports Second Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q2 2026 Financial Results July 29th, 2026 April 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Making Nerve Repair an Expected Standard of Care A commitment to restoring health, improving quality of life, and advancing peripheral nerve care for every patient. July 2026
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Axogen, Inc. Reports First Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q1 2026 Financial Results April 28th, 2026 April 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Making Nerve Repair an Expected Standard of Care A commitment to restoring health, improving quality of life, and advancing peripheral nerve care for every patient. April 2026
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q4 and 2025 Financial Results February 24, 2026 1
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Axogen Announces Proposed Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
Axogen Announces Pricing of Upsized $124 Million
Material agreement · Other events · EX-99.2 to Form 8-K
Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
The Axogen Nerve Repair Algorithm 6 Connection Protection Termination
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Axogen Announces FDA Approval of Biologics License Application for AVANCE ® (acellular nerve allograft–arwx)
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Axogen, Inc. Reports Third Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q3 2025 Financial Results October 29, 2025 1
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Axogen, Inc. Provides Update on FDA Review Timeline for Avance ® Nerve Graft
Regulation FD disclosure · EX-99.1 to Form 8-K
Axogen, Inc. Reports Second Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q2 2025 Financial Results August 5, 2025 1
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Axogen, Inc. Reports 2025 First Quarter Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Axogen Announces Chief Financial Officer Transition
Results of operations · Executive or director change · EX-99.2 to Form 8-K
The Standard of Nerve Care Investor Presentation March 4th, 2025 1
Regulation FD disclosure · EX-99.1 to Form 8-K
Axogen, Inc Reports 2024 Fourth Quarter and Full-Year Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
February 25, 2025 nasdaq: axgn Corporate presentation
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
November 7, 2024 nasdaq: axgn Corporate presentation
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Axogen, Inc. Announces New Leadership Appointments
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Axogen, Inc Reports Second Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
August 8, 2024 nasdaq: axgn Corporate presentation
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Axogen, Inc Reports First Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
May 2, 2024 nasdaq: axgn Corporate presentation
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
March 5, 2024 nasdaq: axgn Corporate presentation
Regulation FD disclosure · EX-99.1 to Form 8-K
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
January 5, 2024 nasdaq: axgn Corporate presentation
Regulation FD disclosure · EX-99.1 to Form 8-K